Fecha de recepción: 27/06/2017 – Fecha de aceptación: 29/07/2017
Domínguez Cantero M1, Celaya Lecea MC1, Saiz Fernández LC2, Garjón Parra J1
1 Servicio de Gestión de la Prestación Farmacéutica. Subdirección de Farmacia. Servicio Navarro de
Salud-Osasunbidea (España)
2 Coordinador de Investigación en Farmacoterapia. Servicio de Gestión de la Prestación Farmacéutica.
Subdirección de Farmacia. Servicio Navarro de Salud-Osasunbidea (España)
Han sido presentados resultados en el XXI Congreso de la Sociedad Española de Farmacéuticos de Atención Primaria 2016.
____
Correspondencia:
Marcelo Domínguez Cantero
Plaza de la Paz, s/n
31002 Pamplona (Navarra)
Correo electrónico: marcelodcantero@gmail.com
____
SUMMARY
Objective: The safety profile of canagliflozin has evolved since its commercialization in Spain. The completion of clinical trials and pharmacovigilance programs have generated new evidence about safety. The aim of our study was to describe suspected adverse reactions drug (ARDs) of canagliflozin, alone or in combination with other antidiabetic agents in patients diagnosed with type 2 diabetes mellitus.
Methods: Retrospective observational study of patients treated with canagliflozin in the region of Navarre (Spain). Electronic medical records were revising in all patients treated with canagliflozin.
Results: 10 out of 39 patients (25.6%) experienced some suspected ARDs: renal function declined <60 ml/min in four patients, hypotension/hypovolemia was registered in one patient and genital/urinary tract infections were recorded in five patients. Genital and urinary tract infections and worsening renal function were the most frequent side effects, leading to drug withdrawal in three patients.
Key Words: Canagliflozin, drug-related side effects and adverse reactions, type 2 diabetes mellitus.
____
Download PDF: Seguridad de canagliflozina en la práctica clínica. Serie de casos